litlas
Log inCreate account

Yohann Loriot

Active 2008–2026

207
Papers
49,755
Citations
77
h-index
187
i10-index

Citations

Citations per year for Yohann Loriot1945: 1 citations1994: 1 citations2001: 4 citations2005: 1 citations2006: 1 citations2007: 1 citations2009: 8 citations2010: 9 citations2011: 39 citations2012: 68 citations2013: 118 citations2014: 132 citations2015: 263 citations2016: 376 citations2017: 536 citations2018: 738 citations2019: 1,931 citations2020: 2,514 citations2021: 2,711 citations2022: 2,331 citations2023: 1,945 citations2024: 3,360 citations2025: 1,736 citations2026: 71 citations1946–1993: no citations, so these years are not shown1995–2000: no citations, so these years are not shown2002–2004: no citations, so these years are not shown2008: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,686 citing papers, 23% of this breakdownChina: 3,919 citing papers, 15.8% of this breakdownFrance: 1,366 citing papers, 5.5% of this breakdownUnited Kingdom: 1,319 citing papers, 5.3% of this breakdownItaly: 1,312 citing papers, 5.3% of this breakdownGermany: 1,123 citing papers, 4.6% of this breakdownCanada: 945 citing papers, 3.8% of this breakdownSpain: 821 citing papers, 3.3% of this breakdownJapan: 804 citing papers, 3.3% of this breakdownNetherlands: 689 citing papers, 2.8% of this breakdownAustralia: 595 citing papers, 2.4% of this breakdownSwitzerland: 548 citing papers, 2.2% of this breakdown
0%23%Other 22.7%

Institutions

Fields

  • Medicine66.2%
  • Biochemistry, Genetics and Molecular Biology24%
  • Immunology and Microbiology6%
  • Engineering0.9%
  • Computer Science0.4%
  • Health Professions0.4%
  • Other2.1%

Topics

  • Cancer Immunotherapy and Biomarkers12.6%
  • Prostate Cancer Treatment and Research4.5%
  • Gut microbiota and health4.1%
  • Bladder and Urothelial Cancer Treatments4.1%
  • Immunotherapy and Immune Responses3.7%
  • Cancer Genomics and Diagnostics2.8%
  • Other68.2%

Coauthors

All papers

Open in search
  1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Authors: Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P.M. Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, María Paula Roberti, Marine Fidelle, Caroline Flament, Vichnou Poirier-Colame, Paule Opolon, Christophe Klein, Kristina Iribarren, Laura Mondragón, Nicolas Jacquelot, Bo Qu, Gladys Ferrere, Céline Clémenson, Laura Mezquita, J. Remon Masip, Charles Naltet, Solenn Brosseau, Courèche Kaderbhaï, Corentin Richard, Hira Rizvi, Florence Levenez, Nathalie Galleron, Benoît Quinquis, Nicolas Pons, Bernhard Ryffel, Véronique Minard-Colin, Patrick Gonin, Jean‐Charles Soria, Éric Deutsch, Yohann Loriot, François Ghiringhelli, Gérard Zalcman, François Goldwasser, Bernard Escudier, Matthew D. Hellmann, Alexander Eggermont, Didier Raoult, Laurence Albigès, Guido Kroemer, Laurence Zitvogel - Science 2017 cited by 5,594

  2. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

    Authors: Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E. Kadel, Hartmut Koeppen, Jillian L. Astarita, Rafael Cubas, Suchit Jhunjhunwala, Romain Banchereau, Yagai Yang, Yinghui Guan, Cécile Chalouni, James Ziai, Yasin Şenbabaoğlu, Stephen P. Santoro, Daniel Sheinson, Jeffrey Hung, Jennifer M. Giltnane, Andrew A. Pierce, Kathryn Mesh, Steve Lianoglou, Johannes Riegler, Richard A.D. Carano, Pontus Eriksson, Mattias Höglund, Loan Somarriba, Daniel L. Halligan, Michiel S. van der Heijden, Yohann Loriot, Jonathan E. Rosenberg, Lawrence Fong, Ira Mellman, Daniel S. Chen, Marjorie Green, Christina Louise Derleth, Gregg Fine, Priti S. Hegde, Richard Bourgon, Thomas Powles - Nature 2018 cited by 5,616

  3. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    Authors: Thomas Powles, Jonathan E. Rosenberg, Guru Sonpavde, Yohann Loriot, Ignacio Durán, Jae‐Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Chunzhang Wu, Mary S. Campbell, Maria Matsangou, Daniel P. Petrylak - New England Journal of Medicine 2021 cited by 1,155

  4. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

    Authors: Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, Daniel Castellano, Giuseppe Fornarini, Jian‐Ri Li, Mahmut Gümüş, Nataliya Mar, Yohann Loriot, Aude Fléchon, Ignacio Durán, Alexandra Drakaki, Sujata Narayanan, Xuesong Yu, Seema Rao Gorla, Blanca Homet Moreno, Michiel S. van der Heijden - New England Journal of Medicine 2024 cited by 914

  5. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

    Authors: Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan, Christophe Rey, Antoine Bougoüin, Sophie Cousin, Sylvestre Le Moulec, Benjamin Besse, Yohann Loriot, Mathieu Larroquette, Isabelle Soubeyran, Maud Toulmonde, Guilhem Roubaud, Simon Pernot, Mathilde Cabart, François Chomy, Corentin Lefevre, Kévin Bourcier, Michèle Kind, Ilenia Giglioli, Catherine Sautès‐Fridman, Valérie Velasco, Félicie Courgeon, Ezoglin Oflazoglu, Ariel Savina, Aurélien Marabelle, Jean‐Charles Soria, Carine Bellera, Casimir Ledoux Sofeu, Alban Bessede, Wolf H. Fridman, François Le Loarer, Antoîne Italiano - Nature Cancer 2021 cited by 569

  6. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    Authors: Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Robert J Laliberte, Jing Wang, Bo Huang, Craig B. Davis, Camilla Fowst, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Petros Grivas - New England Journal of Medicine 2020 cited by 1,479

  7. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    Authors: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 cited by 3,714

  8. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    Authors: Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman‐Censits, José Luis Perez‐Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Ignacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 cited by 2,211

  9. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Authors: Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf, Yohann Loriot, Cora N. Sternberg, Celestia S. Higano, Peter Iversen, Suman Bhattacharya, Joan Carles, Simon Chowdhury, Ian D. Davis, Johann S. de Bono, Christopher P. Evans, Karim Fizazi, Anthony M. Joshua, Choung‐Soo Kim, Go Kimura, Paul N. Mainwaring, Harry H. Mansbach, Kurt Miller, Sarah B. Noonberg, Frank Perabo, De Phung, Fred Saad, Howard I. Scher, Mary‐Ellen Taplin, Peter Venner, Bertrand Tombal - New England Journal of Medicine 2014 cited by 3,031

  10. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

    Authors: Yohann Loriot, Andrea Necchi, Se Hoon Park, Jesús García-Donás, Robert Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh, Begoña Mellado, Sergey Varlamov, Monika Joshi, Ignacio Durán, Scott T. Tagawa, Yousef Zakharia, Bob Zhong, Kim Stuyckens, Ademi Santiago-Walker, Peter De Porre, Anne O’Hagan, Anjali Narayan Avadhani, Arlene O. Siefker‐Radtke - New England Journal of Medicine 2019 cited by 1,365

  11. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

    Authors: Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Quan Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas - Journal of Clinical Oncology 2021 cited by 533

  12. Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Authors: Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N., Robert J. Jones, Oscar B. Goodman, Fred Saad, John Staffurth, Paul N. Mainwaring, Stephen Harland, Thomas W. Flaig, Thomas E. Hutson, Tina Cheng, Helen Patterson, John D. Hainsworth, Charles J. Ryan, Cora N. Sternberg, Susan Ellard, Aude Fléchon, Mansoor N. Saleh, Mark C. Scholz, Eleni Efstathiou, Andrea Zivi, Diletta Bianchini, Yohann Loriot, Nicole Chieffo, Thian Kheoh, Christopher M. Haqq, Howard I. Scher - New England Journal of Medicine 2011 cited by 4,394

  13. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

    Authors: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Rafael Morales‐Barrera, Aude Fléchon, Şeyda Gündüz, Yohann Loriot, Alejo Rodríguez‐Vida, Ronac Mamtani, Evan Y. Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, D. Cascallar, Mirta Varela, Mauricio Fernández Lazzaro, Diego Kaen, Gabriela Gatica, David Hugo Flores, Agustín Falco, Matias Molina, F. Van Aelst, Christof Vulsteke, Brieuc Sautois, Jean‐Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sérgio Jobim Azevedo, GISELE LOPES MARINHO, João Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, André P. Fay, Joel Gingerich, Yves Fradet, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, José Luis Leal, Francisco Francisco, Carolina Ibáñez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Fléchon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross‐Goupil, Stéphane Culine, Yohann Loriot, Gwénaëlle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David G. Pfister, Carsten Ohlman, Michael Stöeckle, Manfred P. Wirth, Anja Lorch, Guenter Niegisch, Peter J. Goebell, Martin Boegemann, Axel S. Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian A. Thomas, Thomas Hoefner, András Telekes, Judit Kósa, János Révész, Gyorgy Bodoky, Tibor Csőszi, András Csejtei, Lajos Géczi, Ágnes Ruzsa, Zsuzsanna Kolonics, József Erfán, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger and 158 more - The Lancet Oncology 2021 cited by 648

  14. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Tom Powles, Joaquim Bellmunt, Éva Compérat, Maria De Santis, Robert Huddart, Yohann Loriot, Andrea Necchi, Begoña P. Valderrama, Alain Ravaud, Shahrokh F. Shariat, Bernadett Szabados, Michiel S. van der Heijden, Silke Gillessen - Annals of Oncology 2021 cited by 525

  15. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

    Authors: Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, Robert Huddart, Earle F. Burgess, Nadine Houédé, Séverine Banek, Valentina Guadalupi, Ja Hyeon Ku, Begoña P. Valderrama, Ben Tran, Spyros Triantos, Yin Kean, Sydney Akapame, Kris Deprince, Sutapa Mukhopadhyay, Nicole L. Stone, Arlene O. Siefker‐Radtke - New England Journal of Medicine 2023 cited by 291

  16. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

    Authors: Thomas Powles, Ignacio Durán, Michiel S. van der Heijden, Yohann Loriot, Nicholas J. Vogelzang, Ugo De Giorgi, Stéphane Oudard, Margitta Retz, Daniel Castellano, Aristotelis Bamias, Aude Fléchon, Gwénaëlle Gravis, Syed A. Hussain, Toshimi Takano, Ning Leng, Edward E. Kadel, Romain Banchereau, Priti S. Hegde, Sanjeev Mariathasan, Na Cui, Xiaodong Shen, Christina Louise Derleth, Marjorie C. Green, Alain Ravaud - The Lancet 2017 cited by 1,416

  17. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Authors: Thomas Powles, Joseph P. Eder, Gregg Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel P. Petrylak, Siew-leng Melinda Teng, Xiaodong Shen, Zachary Boyd, Priti S. Hegde, Daniel S. Chen, Nicholas J. Vogelzang - Nature 2014 cited by 2,430

  18. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

    Authors: Jordi Rodón, Jean‐Charles Soria, Raanan Berger, Wilson H. Miller, Eitan Rubin, Aleksandra Kugel, Apostolia M. Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña, Yohann Loriot, Mohammad Afshar, Vincent A. Miller, Fanny Wunder, Catherine Bresson, Jean-François Martini, Jacques Raynaud, John Mendelsohn, Gerald Batist, Amir Onn, Josep Tabernero, Richard L. Schilsky, Vladimir Lazar, J. Jack Lee, Razelle Kurzrock - Nature Medicine 2019 cited by 597

  19. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

    Authors: Christophe Massard, Stefan Michiels, Charles Ferté, Marie‐Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loïc Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari, Maud Ngo‐Camus, Rastislav Bahleda, Anas Gazzah, Andrea Varga, Sophie Postel‐Vinay, Yohann Loriot, Caroline Even, Ingrid Breuskin, Nathalie Auger, Bastien Job, Thierry de Baère, Frédèric Deschamps, Philippe Vielh, Jean‐Yves Scoazec, Vladimir Lazar, Catherine Richon, Vincent Ribrag, Éric Deutsch, Eric Angevin, Gilles Vassal, Alexander M.M. Eggermont, Fabrice André, Jean‐Charles Soria - Cancer Discovery 2017 cited by 776

  20. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Authors: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli and 127 more - The Lancet Oncology 2020 cited by 498

  21. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    Authors: Shubham Pant, Martin Schüler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Toshihiko Doi, Josep Tabernero, David A. Reardon, Christophe Massard, Anna Minchom, Iwona Ługowska, Omar Carranza, Dirk Arnold, Martin Gutierrez, Helen Winter, Kim Stuyckens, Lauren Crow, Saltanat Najmi, Constance Hammond, Shibu Thomas, Ademi Santiago-Walker, Spyros Triantos, Hussein Sweiti, Yohann Loriot, Omar Carranza, Martin Alberto Greco, Omar Carranza, Anthony M. Joshua, Christos S. Karapetis, Christopher D. Hart, Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Jing Huang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean‐Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang and 33 more - The Lancet Oncology 2023 cited by 200

  22. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

    Authors: Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell, Jae‐Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. Harrison, Se Hoon Park, David I. Quinn, Elisabeth I. Heath, Jonathan E. Rosenberg, Joyce Steinberg, Shang-Ying Liang, Janet Trowbridge, Mary S. Campbell, Bradley A. McGregor, Arjun Vasant Balar - The Lancet Oncology 2021 cited by 267

  23. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

    Authors: Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Jing Wang, Bo Huang, Robert J Laliberte, Alessandra di Pietro, Petros Grivas - Journal of Clinical Oncology 2023 cited by 211

  24. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    Authors: Jonathan E. Rosenberg, Thomas Powles, Guru Sonpavde, Yohann Loriot, Ignacio Durán, J.-L. Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Ronac Mamtani, Chunzhang Wu, Maria Matsangou, Mary S. Campbell, Daniel P. Petrylak - Annals of Oncology 2023 cited by 153